0001104659-18-041344.txt : 20180620
0001104659-18-041344.hdr.sgml : 20180620
20180620194127
ACCESSION NUMBER: 0001104659-18-041344
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180620
FILED AS OF DATE: 20180620
DATE AS OF CHANGE: 20180620
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ratcliffe Liam
CENTRAL INDEX KEY: 0001547100
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38535
FILM NUMBER: 18910586
MAIL ADDRESS:
STREET 1: C/O NEW LEAF VENTURE PARTNERS
STREET 2: 7 TIMES SQUARE - SUITE 3502
CITY: NEW YORK
STATE: NY
ZIP: 10036
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aptinyx Inc.
CENTRAL INDEX KEY: 0001674365
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474626057
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1801 MAPLE AVENUE
STREET 2: SUITE 4300
CITY: EVANSTON
STATE: IL
ZIP: 60201
BUSINESS PHONE: 847-871-0377
MAIL ADDRESS:
STREET 1: 909 DAVIS STREET
STREET 2: SUITE 600
CITY: EVANSTON
STATE: IL
ZIP: 60201
3
1
a3.xml
3
X0206
3
2018-06-20
0
0001674365
Aptinyx Inc.
APTX
0001547100
Ratcliffe Liam
C/O APTINYX INC.
909 DAVIS STREET, SUITE 600
EVANSTON
IL
60201
1
0
1
0
Series A-1 Convertible Preferred Stock
Common Stock
1047450
I
See footnotes
Series A-2 Convertible Preferred Stock
Common Stock
1197076
I
See footnotes
Series B Convertible Preferred Stock
Common Stock
552208
I
See footnotes
Series B Convertible Preferred Stock
Common Stock
243345
I
See footnote
All series of convertible preferred stock will automatically convert into the number of shares of the Issuer's common stock on a 27.58621-for-1 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. ("NLVA-III"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. ("Management-III"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a "Manager" and collectively, the "Managers") and may each be deemed to have shared voting and investment power with respect to these securities.
The Reporting Person and each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
These shares are held directly by New Leaf Ventures Biopharma Opportunities I, L.P. ("NLV Biopharma"). The general partner of NLV Biopharma is New Leaf BPO Associates I, L.P. ("NLBA-I"). The general partner of NLBA-I is Management-III. Each of NLVB-I and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVB-I or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person and each of the Managers may be deemed to have shared voting and investment power with respect to these securities. Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
/s/ Craig Slutzkin, attorney-in-fact for Liam Ratcliffe
2018-06-20